17. (a) Muller-Schiffmann, A.; Marz-Berberich, J.; Andreyeva, A.;
Ronicke, R.; Bartnik, D.; Brener, O.; Kutzsche, J.; Horn, A. H. C.;
Hellmert, M.; Polkowska, J.; Gottmann, K.; Reymann, K. G.;
Funke, S. A.; Nagel-Steger, L.; Moriscot, C.; Schoehn, G; Sticht,
H.; Willbold, D.; Schrader, T.; Korth, C. Angew. Chem. Int. Ed.
2010, 49, 8743. (b) Viegas-Junior, C.; Danuello, A.; Bolzani, V.
S.; Barreiro, E. J.; Fraga, C. A. Curr. Med. Chem. 2007, 14, 1829.
(c) Tsogoeva, B.; Svetlana. Mini-Rev. Med. Chem. 2010, 10, 773.
(d) Morphy, M.; Kay, C.; Rankovic, Z. Drug Discov. Today 2004,
9, 641. (e) Punganuru, S. R.; Madala, H. R.; Srivengopal, K. S.
Chem. (los angeles) 2016, 6, 165. (f) Singh, P.; Kaur, M.; Verma,
P. Bioorg. Med. Chem. Lett. 2009, 19, 3054. (g) Shaveta, Mishra,
S.; Singh, P. Eur. J. Md. Chem. 2016, 124, 500.
Therefore, from a series of rationally designed pyrrole –
indole hybrids, we were able to identify a highly potent molecule
that was capable to inhibit the growth of breast cancer cells.
Compound 3a exhibited GI50 for breast cancer cells in the nM
range; 35 nM and 63 nM, respectively for MCF7 and MDA-MB-
468 cell lines. Further studies on compound 3a using the animal
models and the compound – TK interaction studies are underway.
Acknowledgments
Financial assistance in the form of sponsoring research
projects by DST, New Delhi and CSIR, New Delhi is gratefully
acknowledged. JK acknowledge DST, New Delhi for fellowship.
University Grants Commission, New Delhi is acknowledged for
grant under University with potential for Excellence to Guru
Nanak Dev University. NCI Bethesda USA is gratefully
acknowledged for anti-cancer studies.
18. Bhardwaj, V.; Gumber, D; Abbot, V.; Dhiman, S.; Sharma, P.
RSC Adv. 2015, 5, 15233.
19. Fang, Z.; Liao, P-C.; Yang, F-L; Chen, Y-C; Lam, Y; Hua, K-F.;
Wu, S-H. J. Med Chem. 2010, 53, 7967.
20. Qian, X; Liang, G-B.; Fisher, M.; Crumbley, T.; Rattrey, S.;
Dulski, P. M.; Gurnett, A.; Leavitt, P. S.; Liberator, P. A.; Misura,
A. S.; Samaras, S.; Tamas, T.; Schmatz, D. M.; Wyvratt, M.;
Biftu, T. Bioorg. Med. Chem. Lett. 2006, 16, 2817.
21. Regina, G. L.; Ruoli, B.; Coluccia, A.; Famiglini, V.; Pelliccia, S.;
Passacantilli, S.; Mazzoccoli, C.; Ruggieri, V.; Sisinni, L.;
Bolognesi, A.; Rensen, W. M.; Miele, A.; Nalli, M.; Alfonsi, R.;
Marcotulllio, L. D.; Gulino, A; Brancale, A.; Novellino, E.;
Dondio, G.; Vultaggio, S.; Varasi, M.; Mercuri, C.; Hamel, E.;
Lavia, P.; Silvertri, R. J. Med. Chem. 2014, 57, 6531.
References and notes
1. (a) World Health Statistic 2012. World health Organisation
Geneva, 2012. (b) Jemal, A.; Bray, F.; M, M.; Ferlay, J.; Ward, E.;
Forman, D. Global Cancer Statistics. CA Cancer J. Clin. 2011, 61,
69.
2. (a) Siegel, R. L.; Miller, K. D.; Jemal, A. CA Cancer J. Clin.
2017, 67, 7. (b) Cancer Facts & Figures 2017. Atlanta: American
Cancer Society.
22. (a) Sharma, V.; Kumar, P.; Pathak, D. J. Heterocyclic Chem.
2010, 47, 491. (b) Zhuang, S-H.; Lin, Y-C.; Chou, L-C.; Hsu, M-
H.; Lin, H-Y.; Huang, C-H.; Lien, J-C.; Kuo, S-C.; Huang, L-J.
Eur. J. Med. Chem. 2013, 66, 466. (c) Schuk, D. C.; Jorao, A. K.;
Nakabashi, M.; Cunha, A. C.; Ferreira, V. F.; Garcia, C. R. S. Eur.
J. Med. Chem. 2014, 78, 375. (d) Kaushik, N. K.; Kaushik, N.;
Attri, P.; Kumar, N.; Kim, C. H.; Verma, A. K.; Choi, E. H.
Molecules 2013, 18, 6620.
3. (a) Devita, V. T.; Jr.; Chu, E. Cancer Res. 2008, 68, 8643. (b)
Isakoff, S. J. Cancer J. 2010, 16, 53.
4. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A.
T. J. Am. Chem. Soc. 1971, 93, 2325.
5. Zhou, X-J.; Rahmani, R. Drugs 1992, 44, 1.
23. Laird, A. D.; Vajkoczy, P.; Laura, K. S.; Thurner, A.; Liang, C.;
Mahammadi, M.; Schleessinger, S; Ullrich, A.; Hubbard, S. R.;
Blake, R. A.; Fong, T. A. T.; Strawn, L. M.; Sun, L.; Tang, C.;
Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K. P.; McMahon, G.;
Cherrington, J. M. Cancer Res. 2000, 60, 4152.
6. Kato, T.; Suzumura, Y. J. Nat. Cancer Inst. 1987, 79, 527.
7. Arnold, A. M.; Whitehouse, J. M. A. The Lancet 1981, 318, 912.
8. (a) Potmesil, M. Cancer Res. 1994, 54, 1431. (b) Greenwald, R.
B.; Pendri, A.; Conover, C.; Gilbert, C.; Yang, R.; Xia, J. J. Med.
Chem. 1996, 39, 1938.
24. Parkash, C. R.; Raja, S. Mini-Rev. Med. Chem. 2012, 12, 98.
25. Fong, T. A. T. F.; Shawver, L. K.; Li, S.; Tang, C.; App, H.;
Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.;
Ullrich, A.; Hirth, K. P.; MacMahon, G. Cancer Res. 1999, 59, 99.
26. (a) Sun, L.; Liang, C.; Sheri, S.; Zhou, Y.; Miller, T.; Lui, J.;
Fukuda, J. Y.; Chu, J-Y.; Nematalla, A.; Wang, X.; Chen, H.;
Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. J. Med. Chem.
2003, 46, 1116. (b) Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.;
MacMahon, G. J. Med. Chem. 1998, 41, 2588.
9. Shenkenberg, T. D.; Von Hoff, D. D. Ann. Intern. Med. 1986, 105,
67.
10. Heidelberger, C.; Chaudhuri, N. K.; Danneberg, P.; Mooren, D.;
Griesbach, L.; Duschinsky, R.; Schnitzer, R. J.; Pleven, E.;
Scheiner, J. Nature 1957, 179, 663.
11. Fuertes, M. A.; Alonso, C.; Perez, J. M. Chem. Rev. 2003, 103,
645.
12. Brighton, D.; Wood, M. In The Royal Marsden Hospital
Handbook of Cancer Chemotherapy, Johnston, S. R. D.; Ford, H.;
Ross, P. J., Medical Eds.; Elsevier Churchill Livingstone, 2005.
13. (a) Paul, M. K.; Mukhopadhay, A. K. Int. J. Med. Sci. 2004, 1,
101. (b) Lemmon, M. A.; Schlessinger, J. Cell 2010, 141, 1117.
14. (a) Hunter, T. Cell, 2000. 100, 113. (b) Schlessinger, J. Cell, 2000.
103, 211.
Supplementary Material
Experimental data, NMR spectra, HRMS and IR spectra of the
compounds.
15. (a) Nishikawa, R. E. A. Proc Natl Acad Sci, 1994. 91, 7727. (b)
Zwick, E.; Bange, J.; Ullrich, A. Trends Mol Med. 2002, 8, 17. (c)
Kolibaba, K.S.; Druker, B.J. Biochim Biophys Acta, 1997, 1333,
F217. (d) Resnik, J. L.; Reichart, D. B.; Huey, K.; Webster, N. J.;
Seely, B. L. Cancer Res. 1998. 58, 1159.
The number allotted to this Indian Patent
Application is 201611019190
16. Paul, M. K.; Mukhopadhya, A. K. Int. J. Med. Sci. 2004, 1, 101
and references therein.